Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
1.85
Industry P/E
--
Debt to Equity
0
ROE
-3.25 %
ROCE
--
Div. Yield
0 %
Book Value
0.3
EPS
-13.24
CFO
$-88.61 Mln
EBITDA
$-123.86 Mln
Net Profit
$-129.38 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Genprex (GNPX)
| -57.34 | -22.87 | -68.68 | -91.33 | -83.73 | -65.62 | -- |
|
BSE Sensex*
| -5.65 | -3.07 | -9.18 | 0.22 | 9.95 | 17.63 | 9.82 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Genprex (GNPX)
| -90.56 | -84.14 | 10.69 | -68.43 | 1,196.88 | -70.91 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.65 | 10,257.64 | 20.82 | 23.13 | |
| 34.62 | 13,507.42 | -- | -28.77 | |
| 110.75 | 11,042.16 | 33.66 | 14.16 | |
| 97.19 | 9,680.89 | 42.64 | 19.71 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations... with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Read more
Co-Founder, Chairman, President & CEO
Mr. John Rodney Varner
Co-Founder, Chairman, President & CEO
Mr. John Rodney Varner
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Genprex Inc (GNPX) stood at $ 6 Mln as on 30-Sep-24
The share price of Genprex Inc (GNPX) is $0.36 (NASDAQ) as of 14-Mar-2025 16:25 EDT. Genprex Inc (GNPX) has given a return of -83.73% in the last 3 years.
Genprex Inc (GNPX) has a market capitalisation of $ 3 Mln as on 14-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Genprex Inc (GNPX) is 1.85 times as on 14-Mar-2025, a 32% discount to its peers’ median range of 2.71 times.
Since, TTM earnings of Genprex Inc (GNPX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Genprex Inc (GNPX) and enter the required number of quantities and click on buy to purchase the shares of Genprex Inc (GNPX).
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
The CEO & director of Mr. John Rodney Varner. is Genprex Inc (GNPX), and CFO & Sr. VP is Mr. John Rodney Varner.
There is no promoter pledging in Genprex Inc (GNPX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Genprex Inc. (GNPX) | Ratios |
|---|---|
|
Return on equity(%)
|
-435.82
|
|
Operating margin(%)
|
-72723.66
|
|
Net Margin(%)
|
-98082.2
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Genprex Inc (GNPX) was $0 Mln.
$0.00
(
